Health Care

A method for:

• (A) deterring in an individual, as the individual ages, the development of a bodily condition which is a pre-cardiovascular indicator of the development of a cardiovascular disease (CVD);
• or
• (B) treating an individual who exhibits a bodily condition which is a pre-cardiovascular indicator of the development of CVD or an individual who has a bodily condition which is possessed by an individual who has CVD;
• wherein said individual:
• (i) ingests one or more drugs which are effective to deter the development of said condition or to reduce the severity of an existing condition;
• and
• (ii) optionally lives a life style which deters also the development of said condition or reduces the severity of an existing condition, the improvement comprising:
• the practice by the individual of a regimen which comprises the ingestion by the individual of:
• (iii) a non-steroidal anti-inflammatory drug (NSAID), namely magnesium salicylate;
• and
• (iv) another NSAID, namely naproxen;
• wherein, on a daily basis, the magnesium salicylate is ingested in an amount of about 80 to about 260 mg and naproxen is ingested in an amount of about 160 to about 600 mg;
• and wherein, on a daily basis, the total amount ingested of said NSAIDs is a pharmaceutically effective amount.

A method for treating an individual who has Type 2 diabetes comprising the practice by the individual of a regimen which includes the ingestion daily by the individual of:

• (A) at least one glucose-lowering drug (G-LD) which functions to lower the amount of glucose in the blood of the individual;
• and
• (B) a non-steroidal anti-inflammatory drug (NSAID), namely magnesium salicylate;
• and optionally an additional NSAID;
• (C) wherein on a daily basis, the G-LD is ingested in an amount of about 1 to about 3000 mg and the magnesium salicylate is ingested in an amount of about 80 to about 260 mg;
• and wherein on a daily basis, the total amount ingested of the G-LD and the NSAID is a pharmaceutically effective amount;
• and
• wherein said individual optionally lives a life style which reduces the severity of undesirable symptoms associated with Type 2 diabetes.

A regimen which is useful for treating an individual to reduce the risk of the development of a cardiovascular disease or the development of Alzheimer's disease or to treat an individual who has a cardiovascular disease or Alzheimer's disease, the regimen being in a form for oral ingestion by an individual and comprising:

• (A) about 80 to about 260 mg of a non-steroidal anti-inflammatory drug (NSAID), namely magnesium salicylate;
• (B) about 160 to about 600 mg of another non-steroidal anti-inflammatory drug, namely naproxen;
• and optionally
• (C) one or more additional NSAIDs in an amount no greater than about 20 wt. % of the total amount of the NSAIDs comprising the regimen.